Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab

Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab

BackgroundSintilimab, a programmed cell death protein-1 (PD-1) inhibitor, has shown efficacy in non-small cell lung cancer (NSCLC), though response heterogeneity persists. Previous studies suggest that the Lung Immune Prognostic Index (LIPI) may predict prognosis and immune-related adverse events (i...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Xu, Tingting Peng, Kaikai Fan, Yuxiao Dou, Lingti Kong, Ran Sang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
nomograms
non-small cell lung cancer
immunotherapy
inflammation markers
predicting
sintilimab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1569689/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items